<p>隨着全球市場繼續應對貨幣政策變化和經濟數據的影響，亞洲市場表現出韌性，科技和製造等行業活動顯著。儘管歷史上有負面含義，便士股票仍然被視為發現新興公司的一個重要投資領域。這些較小或較新的公司在強大的財務健康支持下，可以提供增長機會，為投資者帶來顯著回報的潛力。</p>
<h3>亞洲十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.00</td>
<td>THB3.95B</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$3.05</td>
<td>HK$2.48B</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.61</td>
<td>HK$995.82M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.49</td>
<td>HK$2.07B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.97</td>
<td>SGD393.13M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>T.A.C. Consumer (SET:TACC)</td>
<td>THB4.96</td>
<td>THB2.98B</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.18</td>
<td>SGD12.52B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.98</td>
<td>THB1.44B</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Lum Chang Holdings (SGX:L19)</td>
<td>SGD0.43</td>
<td>SGD161.09M</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們亞洲便士股票篩選器的 976 只股票的完整列表。</p>
<p>以下是篩選器中一些選擇的預覽。</p>
<h2>Cosmos Group (SZSE:002133)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Cosmos Group Co., Ltd. 在中國的房地產開發行業運營，市值為 CN¥28.7 億。</p>
<p><strong>運營：</strong> 公司的收入主要來自其房地產部門，達到 CN¥32.7 億，以及其交易活動的 CN¥19 億。</p>
<p><strong>市值：</strong> CN¥28.7B</p>
<p>Cosmos Group Co., Ltd. 在其財務結構上表現出韌性，短期資產為 CN¥62 億，足以覆蓋短期和長期負債。儘管公司未盈利，但在 2025 年上半年報告了淨收入 CN¥9066 萬，較去年虧損有顯著改善。最近的高管變動和對公司章程的提議修訂可能表明旨在加強治理和運營效率的戰略轉變。公司的分紅提案反映了儘管收益未能完全覆蓋，但仍努力為股東回報價值，突顯了與其財務可持續性戰略相關的潛在風險。</p>
<ul>
<li>在這裏深入瞭解 Cosmos Group 的具體情況，查看我們的全面資產負債表健康報告。</li>
<li>查看我們的歷史業績報告，以獲取 Cosmos Group 的業績記錄的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a8f7b22a-78a2-4ab2-af45-17f92f677dbe/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a8f7b22a-78a2-4ab2-af45-17f92f677dbe/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002133 户債務與股本歷史及分析截至 2025 年 9 月</p>
<h2>天津追日藥業有限公司 (SZSE:300026)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 天津追日藥業有限公司從事藥品的研究、開發、生產和銷售，業務覆蓋中國及國際市場，市值為 CN¥117.8 億。</p>
<p><strong>運營：</strong> 天津追日藥業有限公司未報告具體的收入細分。</p>
<p><strong>市值：</strong> CN¥117.8B</p>
<p>天津追日藥業有限公司展現出穩健的財務狀況，短期資產為 CN¥60 億，超過其短期和長期負債。公司的債務管理良好，由運營現金流覆蓋，且現金超過總債務。儘管過去五年虧損增加，公司在 2025 年上半年報告了淨收入 CN¥7863 萬，較去年有所下降。預計其收益將顯著增長，儘管當前的負股本回報和分紅可持續性對尋求穩定的便士股票投資者構成挑戰。</p>
<ul>
<li>在我們的財務健康報告中更詳細地瞭解天津追日藥業有限公司的潛力。</li>
<li>通過訪問我們的收益增長報告評估天津追日藥業有限公司的前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/56aef653-29e7-46d0-8533-ca47e06dfb33/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/56aef653-29e7-46d0-8533-ca47e06dfb33/chart/financial-position-analysis"/></p>
<p>SZSE:300026 財務狀況分析截至 2025 年 9 月</p>
<h2>永益健康 (SZSE:300247)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 永益健康有限公司在中國從事桑拿產品的製造、出口和銷售，市值為 CN¥37.1 億。</p>
<p><strong>運營：</strong> 永益健康有限公司未報告具體的收入細分。</p>
<p><strong>市值：</strong> CN¥37.1B</p>
<p>永益健康有限公司展現出強大的財務基礎，短期資產為 CN¥9.989 億，超過其短期和長期負債，並且沒有債務。公司表現出令人印象深刻的收益增長，過去一年增長 92%，淨利潤率提高至 8.3%。儘管董事會經驗較少，平均任期為 2.8 年，但管理團隊經驗豐富。2025 年上半年的最新收益報告顯示，收入為 CN¥4.3276 億，反映出在中國桑拿產品市場的強勁運營表現，儘管治理修訂仍在進行中。</p>
<ul>
<li>在這裏深入瞭解永益健康的完整分析健康報告。</li>
<li>通過我們的公司歷史業績報告獲取永益健康的過去趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2605bae5-5579-42d6-8c29-80393c734ae8/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2605bae5-5579-42d6-8c29-80393c734ae8/chart/financial-position-analysis"/></p>
<p>深交所：300247 財務狀況分析截至 2025 年 9 月</p>
<h2>利用優勢</h2>
<ul>
<li>在這裏瀏覽 976 只亞洲便士股票的完整清單。</li>
<li>考慮其他策略？探索 24 家在下一代技術革命中處於領先地位的量子計算公司，這些公司通過量子算法、超導量子比特和前沿研究塑造未來。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

健倍苗苗

利華控股集團

<p>這篇文章討論了三隻市值低於 20 億美元的亞洲便士股票，強調了它們儘管歷史上存在風險，但仍具有增長潛力。這些股票包括 Food Moments、健倍苗苗和利華控股集團，每個公司在各自的行業中都表現出韌性。文章強調了這些小型公司的財務健康的重要性，指出它們可以為投資者提供顯著的回報。此外，文章還提供了關於其他公司如 Cosmos Group 和天津追日藥業的財務狀況的見解，展示了它們的運營表現和麪臨的挑戰</p>

<p>As global markets continue to navigate the impacts of monetary policy shifts and economic data, Asian markets have shown resilience with notable activity in sectors like technology and manufacturing. Penny stocks, often seen as a gateway to discovering emerging companies, remain a compelling investment area despite their historical connotations. These smaller or newer companies can offer growth opportunities when backed by strong financial health, providing investors with the potential for significant returns.</p>
<div class="lb-trans"><p>隨着全球市場繼續應對貨幣政策變化和經濟數據的影響，亞洲市場表現出韌性，科技和製造等行業活動顯著。儘管歷史上有負面含義，便士股票仍然被視為發現新興公司的一個重要投資領域。這些較小或較新的公司在強大的財務健康支持下，可以提供增長機會，為投資者帶來顯著回報的潛力。</p>
</div><h3>Top 10 Penny Stocks In Asia</h3>
<div class="lb-trans"><h3>亞洲十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.00</td>
<td>THB3.95B</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$3.05</td>
<td>HK$2.48B</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.61</td>
<td>HK$995.82M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.49</td>
<td>HK$2.07B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.97</td>
<td>SGD393.13M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>T.A.C. Consumer (SET:TACC)</td>
<td>THB4.96</td>
<td>THB2.98B</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.18</td>
<td>SGD12.52B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.98</td>
<td>THB1.44B</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Lum Chang Holdings (SGX:L19)</td>
<td>SGD0.43</td>
<td>SGD161.09M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.00</td>
<td>THB3.95B</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$3.05</td>
<td>HK$2.48B</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.61</td>
<td>HK$995.82M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.49</td>
<td>HK$2.07B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.97</td>
<td>SGD393.13M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>T.A.C. Consumer (SET:TACC)</td>
<td>THB4.96</td>
<td>THB2.98B</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.18</td>
<td>SGD12.52B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.98</td>
<td>THB1.44B</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Lum Chang Holdings (SGX:L19)</td>
<td>SGD0.43</td>
<td>SGD161.09M</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 976 stocks from our Asian Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們亞洲便士股票篩選器的 976 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是篩選器中一些選擇的預覽。</p>
</div><h2>Cosmos Group (SZSE:002133)</h2>
<div class="lb-trans"><h2>Cosmos Group (SZSE:002133)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Cosmos Group Co., Ltd. operates in the real estate development sector in China with a market capitalization of CN¥2.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Cosmos Group Co., Ltd. 在中國的房地產開發行業運營，市值為 CN¥28.7 億。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its real estate segment at CN¥3.27 billion and its trading activities at CN¥1.90 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其房地產部門，達到 CN¥32.7 億，以及其交易活動的 CN¥19 億。</p>
</div><p><strong>Market Cap:</strong> CN¥2.87B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥28.7B</p>
</div><p>Cosmos Group Co., Ltd. has shown resilience in its financial structure, with short-term assets of CN¥6.2 billion comfortably covering both short-term and long-term liabilities. Despite being unprofitable, the company reported a net income of CN¥90.66 million for the first half of 2025, a significant improvement from a loss last year. Recent executive changes and proposed amendments to company bylaws may signal strategic shifts aimed at strengthening governance and operational efficiency. The company's dividend proposal reflects an effort to return value to shareholders despite earnings not fully covering it, highlighting potential risks associated with its financial sustainability strategy.</p>
<div class="lb-trans"><p>Cosmos Group Co., Ltd. 在其財務結構上表現出韌性，短期資產為 CN¥62 億，足以覆蓋短期和長期負債。儘管公司未盈利，但在 2025 年上半年報告了淨收入 CN¥9066 萬，較去年虧損有顯著改善。最近的高管變動和對公司章程的提議修訂可能表明旨在加強治理和運營效率的戰略轉變。公司的分紅提案反映了儘管收益未能完全覆蓋，但仍努力為股東回報價值，突顯了與其財務可持續性戰略相關的潛在風險。</p>
</div><ul>
<li>Dive into the specifics of Cosmos Group here with our thorough balance sheet health report.</li>
<li>Review our historical performance report to gain insights into Cosmos Group's track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解 Cosmos Group 的具體情況，查看我們的全面資產負債表健康報告。</li>
<li>查看我們的歷史業績報告，以獲取 Cosmos Group 的業績記錄的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a8f7b22a-78a2-4ab2-af45-17f92f677dbe/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/a8f7b22a-78a2-4ab2-af45-17f92f677dbe/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002133 Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>SZSE:002133 户債務與股本歷史及分析截至 2025 年 9 月</p>
</div><h2>Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026)</h2>
<div class="lb-trans"><h2>天津追日藥業有限公司 (SZSE:300026)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Tianjin Chase Sun Pharmaceutical Co., Ltd is involved in the research, development, production, and sale of pharmaceutical products both in China and internationally, with a market cap of CN¥11.78 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 天津追日藥業有限公司從事藥品的研究、開發、生產和銷售，業務覆蓋中國及國際市場，市值為 CN¥117.8 億。</p>
</div><p><strong>Operations:</strong> No specific revenue segments are reported for Tianjin Chase Sun Pharmaceutical Co., Ltd.</p>
<div class="lb-trans"><p><strong>運營：</strong> 天津追日藥業有限公司未報告具體的收入細分。</p>
</div><p><strong>Market Cap:</strong> CN¥11.78B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥117.8B</p>
</div><p>Tianjin Chase Sun Pharmaceutical Co., Ltd. demonstrates a solid financial position with short-term assets of CN¥6 billion exceeding both its short and long-term liabilities. The company's debt is well-managed, covered by operating cash flow, and it has more cash than total debt. Despite being unprofitable with increased losses over the past five years, the company reported net income of CN¥78.63 million for the first half of 2025, down from last year. Its earnings are forecast to grow significantly annually, though current negative return on equity and dividend sustainability pose challenges for investors seeking stability in penny stocks.</p>
<div class="lb-trans"><p>天津追日藥業有限公司展現出穩健的財務狀況，短期資產為 CN¥60 億，超過其短期和長期負債。公司的債務管理良好，由運營現金流覆蓋，且現金超過總債務。儘管過去五年虧損增加，公司在 2025 年上半年報告了淨收入 CN¥7863 萬，較去年有所下降。預計其收益將顯著增長，儘管當前的負股本回報和分紅可持續性對尋求穩定的便士股票投資者構成挑戰。</p>
</div><ul>
<li>Take a closer look at Tianjin Chase Sun PharmaceuticalLtd's potential here in our financial health report.</li>
<li>Evaluate Tianjin Chase Sun PharmaceuticalLtd's prospects by accessing our earnings growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的財務健康報告中更詳細地瞭解天津追日藥業有限公司的潛力。</li>
<li>通過訪問我們的收益增長報告評估天津追日藥業有限公司的前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/56aef653-29e7-46d0-8533-ca47e06dfb33/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/56aef653-29e7-46d0-8533-ca47e06dfb33/chart/financial-position-analysis"/></p>
<p>SZSE:300026 Financial Position Analysis as at Sep 2025</p>
<div class="lb-trans"><p>SZSE:300026 財務狀況分析截至 2025 年 9 月</p>
</div><h2>Youngy Health (SZSE:300247)</h2>
<div class="lb-trans"><h2>永益健康 (SZSE:300247)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Youngy Health Co., Ltd. is involved in the manufacture, export, and sale of sauna products in China with a market cap of CN¥3.71 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 永益健康有限公司在中國從事桑拿產品的製造、出口和銷售，市值為 CN¥37.1 億。</p>
</div><p><strong>Operations:</strong> Youngy Health Co., Ltd. does not report specific revenue segments.</p>
<div class="lb-trans"><p><strong>運營：</strong> 永益健康有限公司未報告具體的收入細分。</p>
</div><p><strong>Market Cap:</strong> CN¥3.71B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥37.1B</p>
</div><p>Youngy Health Co., Ltd. showcases a robust financial foundation, with short-term assets of CN¥998.9 million surpassing both its short and long-term liabilities, and it operates without debt. The company has demonstrated impressive earnings growth, with a 92% increase over the past year and net profit margins improving to 8.3%. Despite a less experienced board with an average tenure of 2.8 years, the management team is seasoned. Recent earnings report for the first half of 2025 shows revenue at CN¥432.76 million, reflecting strong operational performance in the sauna product market in China amidst ongoing governance amendments.</p>
<div class="lb-trans"><p>永益健康有限公司展現出強大的財務基礎，短期資產為 CN¥9.989 億，超過其短期和長期負債，並且沒有債務。公司表現出令人印象深刻的收益增長，過去一年增長 92%，淨利潤率提高至 8.3%。儘管董事會經驗較少，平均任期為 2.8 年，但管理團隊經驗豐富。2025 年上半年的最新收益報告顯示，收入為 CN¥4.3276 億，反映出在中國桑拿產品市場的強勁運營表現，儘管治理修訂仍在進行中。</p>
</div><ul>
<li>Jump into the full analysis health report here for a deeper understanding of Youngy Health.</li>
<li>Gain insights into Youngy Health's past trends and performance with our report on the company's historical track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解永益健康的完整分析健康報告。</li>
<li>通過我們的公司歷史業績報告獲取永益健康的過去趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2605bae5-5579-42d6-8c29-80393c734ae8/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/2605bae5-5579-42d6-8c29-80393c734ae8/chart/financial-position-analysis"/></p>
<p>SZSE:300247 Financial Position Analysis as at Sep 2025</p>
<div class="lb-trans"><p>深交所：300247 財務狀況分析截至 2025 年 9 月</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用優勢</h2>
</div><ul>
<li>Navigate through the entire inventory of 976 Asian Penny Stocks here.</li>
<li>Contemplating Other Strategies? Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏瀏覽 976 只亞洲便士股票的完整清單。</li>
<li>考慮其他策略？探索 24 家在下一代技術革命中處於領先地位的量子計算公司，這些公司通過量子算法、超導量子比特和前沿研究塑造未來。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>